Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect

Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/...

Full description

Saved in:
Bibliographic Details
Published inCancer nanotechnology Vol. 12; no. 1; pp. 1 - 35
Main Authors Dabbagh Moghaddam, Farnaz, Akbarzadeh, Iman, Marzbankia, Ehsan, Farid, Mahsa, khaledi, Leila, Reihani, Amir Hossein, Javidfar, Mehrnoosh, Mortazavi, Pejman
Format Journal Article
LanguageEnglish
Published Vienna Springer Vienna 01.12.2021
Springer Nature B.V
BMC
Subjects
Anticancer properties
Apoptosis
Assaying
Biochemistry
Biocompatibility
Biomarkers
Biomedical Engineering and Bioengineering
Breast cancer
Cancer Research
Cancer therapies
Chemistry and Materials Science
Chemotherapy
Drug carriers
Encapsulation
Enzyme activity
Evaluation
Flow cytometry
Free form
Gene expression
Genes
Histopathology
Immunohistochemistry
In vivo methods and tests
Materials Science
Melittin
Mitosis
Morphology
Nano-niosome
Nanotechnology
Polydispersity
Renal and liver enzymes
Toxicity
Wound healing
Immunohistochemistry
Breast cancer
Melittin
Nano-niosome
Renal and liver enzymes
Online AccessGet full text
ISSN1868-6958
1868-6966
DOI10.1186/s12645-021-00085-9

Cover

Abstract Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the niosomes; different niosomal formulations of melittin were prepared and characterized in terms of morphology, size, polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of melittin, and melittin-loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the gene expression. 40 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done. Results This study showed melittin-loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The melittin-loaded niosome affects the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2 , MMP2 , and MMP9 genes while they up-regulate the expression of Bax , Caspase3 and Caspase9 genes. They have also enhanced the apoptosis rate and inhibited cell migration, invasion in both cell lines compared to the melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in melittin-loaded niosome. Renal and hepatic biomarker activity did not significantly differ in melittin-loaded niosome and melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups. Conclusions Our study successfully declares that melittin-loaded niosome had more anti-cancer effects than free melittin. This project has demonstrated that niosomes are suitable vesicle carriers for melittin, compare to the free form.
AbstractList BackgroundMelittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the niosomes; different niosomal formulations of melittin were prepared and characterized in terms of morphology, size, polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of melittin, and melittin-loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the gene expression. 40 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done.ResultsThis study showed melittin-loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The melittin-loaded niosome affects the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2, MMP2, and MMP9 genes while they up-regulate the expression of Bax, Caspase3 and Caspase9 genes. They have also enhanced the apoptosis rate and inhibited cell migration, invasion in both cell lines compared to the melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in melittin-loaded niosome. Renal and hepatic biomarker activity did not significantly differ in melittin-loaded niosome and melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups.ConclusionsOur study successfully declares that melittin-loaded niosome had more anti-cancer effects than free melittin. This project has demonstrated that niosomes are suitable vesicle carriers for melittin, compare to the free form.
Abstract Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the niosomes; different niosomal formulations of melittin were prepared and characterized in terms of morphology, size, polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of melittin, and melittin-loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the gene expression. 40 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done. Results This study showed melittin-loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The melittin-loaded niosome affects the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2, MMP2, and MMP9 genes while they up-regulate the expression of Bax, Caspase3 and Caspase9 genes. They have also enhanced the apoptosis rate and inhibited cell migration, invasion in both cell lines compared to the melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in melittin-loaded niosome. Renal and hepatic biomarker activity did not significantly differ in melittin-loaded niosome and melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups. Conclusions Our study successfully declares that melittin-loaded niosome had more anti-cancer effects than free melittin. This project has demonstrated that niosomes are suitable vesicle carriers for melittin, compare to the free form.
Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the niosomes; different niosomal formulations of melittin were prepared and characterized in terms of morphology, size, polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of melittin, and melittin-loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the gene expression. 40 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done. Results This study showed melittin-loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The melittin-loaded niosome affects the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2 , MMP2 , and MMP9 genes while they up-regulate the expression of Bax , Caspase3 and Caspase9 genes. They have also enhanced the apoptosis rate and inhibited cell migration, invasion in both cell lines compared to the melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in melittin-loaded niosome. Renal and hepatic biomarker activity did not significantly differ in melittin-loaded niosome and melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups. Conclusions Our study successfully declares that melittin-loaded niosome had more anti-cancer effects than free melittin. This project has demonstrated that niosomes are suitable vesicle carriers for melittin, compare to the free form.
ArticleNumber 14
Author Akbarzadeh, Iman
Farid, Mahsa
Reihani, Amir Hossein
Javidfar, Mehrnoosh
Marzbankia, Ehsan
Dabbagh Moghaddam, Farnaz
khaledi, Leila
Mortazavi, Pejman
Author_xml – sequence: 1
  givenname: Farnaz
  surname: Dabbagh Moghaddam
  fullname: Dabbagh Moghaddam, Farnaz
  organization: Department of Biology, Science and Research Branch, Islamic Azad University
– sequence: 2
  givenname: Iman
  surname: Akbarzadeh
  fullname: Akbarzadeh, Iman
  organization: Department of Chemical and Petrochemical Engineering, Sharif University of Technology
– sequence: 3
  givenname: Ehsan
  surname: Marzbankia
  fullname: Marzbankia, Ehsan
  organization: Department of Chemical and Petrochemical Engineering, Sharif University of Technology
– sequence: 4
  givenname: Mahsa
  surname: Farid
  fullname: Farid, Mahsa
  organization: Gastroenterology and Liver Diseases Research Center, Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences
– sequence: 5
  givenname: Leila
  surname: khaledi
  fullname: khaledi, Leila
  organization: Department of Genetic, Tehran North Branch, Islamic Azad University
– sequence: 6
  givenname: Amir Hossein
  surname: Reihani
  fullname: Reihani, Amir Hossein
  organization: Department of Chemical Engineering, Faculty of Engineering, Ferdowsi University of Mashhad
– sequence: 7
  givenname: Mehrnoosh
  surname: Javidfar
  fullname: Javidfar, Mehrnoosh
  organization: Department of Genetic, Tehran North Branch, Islamic Azad University
– sequence: 8
  givenname: Pejman
  surname: Mortazavi
  fullname: Mortazavi, Pejman
  email: sp.mortazavi@gmail.com
  organization: Department of Pathology, Faculty of Specialized Veterinary Science, Science and Research Branch, Islamic Azad University
BookMark eNp9UctuHCEQRJYj2XH8Az4h5TwJDA9DbpHzsmQpl-SMeqDHYjULNrArOV8fdsdJpBx8ohqqqkvUa3KackJCrjh7x7nR7ysftVQDG_nAGDNqsCfkvD-YQVutT_9iZc7IZa2bTmLCWsvsOfn1CZe4x_JE80y3HbcW07BkCBhoirnmLVY650KnglAb9ZA8Ftr61LaY2gcKicZE97GV3HFYh32muIdlBy3mdPCG1OLwLMZ5Rt_ekFczLBUvn88L8vPL5x8334a7719vbz7eDV5a1QbUXjCFUjA2e7BBX0_BsMlra4QK12pUXNhRmiCV8kLoMIkpMDVbkAzAaHFBblffkGHjHkrcQnlyGaI7XuRy76C06Bd0s-YhBM76FpRoYTLdQAo-sWBAs4PX29XroeTHHdbmNnlXUo_vRiWFsXoUrLPMyvIl11pwdj6240-0AnFxnLlDcW4tzvXi3LE4Z7t0_E_6J_CLIrGKaieneyz_Ur2g-g30Pa2F
CitedBy_id crossref_primary_10_1016_j_jep_2023_117093
crossref_primary_10_1016_j_ijbiomac_2023_126808
crossref_primary_10_3390_gels8050315
crossref_primary_10_2174_1567201819666220427132734
crossref_primary_10_1007_s10989_024_10593_y
crossref_primary_10_1007_s11033_022_07199_2
crossref_primary_10_4155_tde_2023_0020
crossref_primary_10_1016_j_bioadv_2024_213903
crossref_primary_10_1038_s41598_024_75183_w
crossref_primary_10_3390_toxins15020165
crossref_primary_10_1016_j_ijbiomac_2023_123686
crossref_primary_10_1002_advs_202102678
crossref_primary_10_1016_j_heliyon_2023_e18710
crossref_primary_10_3390_pharmaceutics17010067
crossref_primary_10_1016_j_mtbio_2023_100837
crossref_primary_10_3390_pharmaceutics16020223
crossref_primary_10_1016_j_biopha_2024_117465
crossref_primary_10_1007_s11033_022_07667_9
crossref_primary_10_1080_1061186X_2022_2032094
crossref_primary_10_1080_14712598_2022_2088277
crossref_primary_10_1177_15280837221112410
crossref_primary_10_3389_fimmu_2024_1510693
crossref_primary_10_1016_j_nantod_2021_101279
crossref_primary_10_1021_acsanm_2c00861
crossref_primary_10_3390_antiox11071318
crossref_primary_10_2147_IJN_S325901
crossref_primary_10_1016_j_ijbiomac_2023_123514
crossref_primary_10_1080_1061186X_2024_2365937
crossref_primary_10_1093_gigascience_giac048
crossref_primary_10_1007_s12010_024_04985_5
crossref_primary_10_1007_s40995_023_01460_4
crossref_primary_10_3389_fphar_2022_1001553
crossref_primary_10_1016_j_jddst_2024_106510
crossref_primary_10_1016_j_jtemb_2024_127469
crossref_primary_10_2174_0109298665339355241008104141
crossref_primary_10_1134_S1068162024030348
crossref_primary_10_1016_j_pestbp_2023_105724
crossref_primary_10_1097_st9_0000000000000054
crossref_primary_10_33483_jfpau_1405409
crossref_primary_10_1016_j_envres_2023_117084
crossref_primary_10_3390_nu15143111
crossref_primary_10_1016_j_aca_2024_343572
crossref_primary_10_1186_s12645_024_00252_8
crossref_primary_10_3389_fbioe_2021_745099
crossref_primary_10_1038_s41598_022_26400_x
crossref_primary_10_3390_jfb13040278
crossref_primary_10_1007_s12032_024_02584_2
crossref_primary_10_1016_j_ijpharm_2022_122345
crossref_primary_10_1007_s40995_024_01731_8
crossref_primary_10_1186_s12645_025_00313_6
crossref_primary_10_1016_j_ijpx_2023_100217
crossref_primary_10_3390_polym15214336
crossref_primary_10_1007_s00210_023_02579_2
crossref_primary_10_1515_nanofab_2020_0100
crossref_primary_10_1016_j_jddst_2025_106711
crossref_primary_10_3390_ijms24098388
crossref_primary_10_1080_02652048_2024_2443435
crossref_primary_10_1007_s12668_024_01739_9
crossref_primary_10_1016_j_envres_2023_117292
crossref_primary_10_1016_j_ejpb_2023_04_016
crossref_primary_10_3389_fonc_2022_926242
crossref_primary_10_1007_s12275_024_00113_4
crossref_primary_10_1016_j_carbpol_2022_120510
crossref_primary_10_1039_D1RA06057K
crossref_primary_10_1007_s12032_022_01836_3
crossref_primary_10_1016_j_arabjc_2023_104704
crossref_primary_10_2147_IJN_S384085
crossref_primary_10_4155_tde_2023_0092
crossref_primary_10_3390_toxins14070460
crossref_primary_10_1080_10408347_2024_2339962
crossref_primary_10_3390_microbiolres14040144
crossref_primary_10_1016_j_apt_2021_10_019
crossref_primary_10_3390_ijms222011122
Cites_doi 10.1016/j.apsb.2011.09.002
10.2174/1568026615666150703115919
10.1016/S0006-3495(82)84681-X
10.1021/bi00532a007
10.2174/1871520620666200211091451
10.1186/s12951-018-0351-4
10.1002/jbm.a.37086
10.1002/jcp.24818
10.1007/s00580-016-2285-2
10.1016/S0006-3495(97)78822-2
10.1016/j.ijpharm.2005.05.009
10.1016/S0041-0101(99)00110-5
10.1158/0008-5472.CAN-09-1947
10.1016/S0006-3495(81)84719-4
10.1093/molehr/4.12.1099
10.1016/j.suc.2012.12.002
10.1080/01635580701419030
10.1186/s13045-017-0442-y
10.1016/j.toxicon.2013.03.011
10.1146/annurev.bi.53.070184.003115
10.1101/2020.09.08.287094
10.1002/wnan.126
10.1080/21691401.2018.1536063
10.1021/bi991225t
10.1007/s00253-016-7400-4
10.1016/j.lfs.2006.09.024
10.1016/j.tiv.2019.104756
10.3892/ol.2016.5516
10.1172/JCI38842
10.1016/j.cis.2012.08.002
10.1111/exd.12384
10.1111/j.1432-1033.1988.tb13977.x
10.1007/s12272-013-0208-1
10.1080/14756366.2016.1268607
10.3390/biology10030173
10.1007/s10549-015-3406-3
10.1186/s12885-018-4230-z
10.1016/j.ejphar.2009.08.043
10.2174/1389450115666141106151143
10.1371/journal.pone.0069380
10.1517/17425241003602259
10.1007/s13277-014-2534-4
10.1002/adhm.201701460
10.1007/s10059-010-0028-9
10.1016/j.jep.2016.04.047
10.1021/acs.bioconjchem.5b00246
10.1021/bi036153r
10.22159/ijap.2020v12i4.37307
10.1002/pros.21296
10.1016/j.toxicon.2007.08.015
10.1016/j.canlet.2017.05.010
10.1073/pnas.0710625105
10.1039/C4TB01401D
10.1074/jbc.M807191200
10.1016/S0006-3495(01)75802-X
10.1089/adt.2019.923
10.1007/s10585-009-9245-z
10.1111/j.2042-7158.1985.tb04990.x
10.3892/mmr.2014.1936
10.1159/000024154
10.5455/ja.20170203075953
10.1016/j.actbio.2015.02.022
10.1016/j.ijpharm.2019.118580
10.1016/j.taap.2011.10.009
10.1016/j.jddst.2020.101715
10.1023/A:1008609513880
10.1002/hep.22240
10.1021/pr060059q
10.1007/BF00258116
10.1016/j.toxlet.2014.06.004
10.3390/v7102883
10.1021/nl073290r
10.3892/mmr.2017.6970
10.1158/1078-0432.CCR-05-2719
10.1371/journal.pone.0125908
10.1016/j.canlet.2009.09.010
10.1016/S0006-3495(96)79622-4
10.1039/C7RA01736G
10.1002/9781119181200
10.1016/S0006-3495(86)83497-X
10.1254/jphs.91.95
10.1007/s10555-011-9339-3
10.1155/2016/6365295
10.1007/s002329900201
10.1016/j.ajps.2015.10.062
10.1002/0471142735.im2002s39
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
8AO
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BENPR
BGLVJ
CCPQU
DWQXO
FYUFA
GHDGH
HCIFZ
K9.
L6V
M0S
M7S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
DOA
DOI 10.1186/s12645-021-00085-9
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
Technology Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
ProQuest Health & Medical Collection
Engineering Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
Engineering Collection
Engineering Database
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1868-6966
EndPage 35
ExternalDocumentID oai_doaj_org_article_f61ddd109d6e4e9ab8a86431b0d8a606
10_1186_s12645_021_00085_9
GroupedDBID ---
-58
-5G
-A0
-BR
0R~
0VY
1N0
2JY
2VQ
30V
3V.
4.4
408
409
40D
7X7
875
8AO
8FE
8FG
8FI
8FJ
8TC
AAFWJ
AAJSJ
AAKKN
AAYZH
ABEEZ
ABJCF
ABUWG
ACACY
ACGFS
ACIWK
ACULB
ADBBV
ADINQ
ADUKV
AFGXO
AFKRA
AFWTZ
AGJBK
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
BAPOH
BCNDV
BENPR
BFQNJ
BGLVJ
BGNMA
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
EBLON
EBS
EJD
F5P
FYUFA
GQ6
GQ8
GROUPED_DOAJ
HCIFZ
HF~
HMCUK
HMJXF
HZ~
IZIGR
KOV
L6V
M4Y
M7S
M~E
NU0
O9-
O93
OK1
P9N
PIMPY
PQQKQ
PROAC
PTHSS
QOS
R9I
RSV
S1Z
S27
S3B
SCM
SOJ
T13
TSV
TUS
U2A
UKHRP
WK8
Z45
Z85
~A9
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQGLB
PQUKI
PRINS
PUEGO
ID FETCH-LOGICAL-c495t-e6c305e4300fca9d67bd80bc69835d7525139248d455c336db3bd05f9a40aa863
IEDL.DBID 7X7
ISSN 1868-6958
IngestDate Wed Aug 27 01:15:14 EDT 2025
Fri Jul 25 11:14:08 EDT 2025
Tue Jul 01 02:42:20 EDT 2025
Thu Apr 24 23:01:53 EDT 2025
Fri Feb 21 02:49:02 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Immunohistochemistry
Breast cancer
Melittin
Nano-niosome
Renal and liver enzymes
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c495t-e6c305e4300fca9d67bd80bc69835d7525139248d455c336db3bd05f9a40aa863
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://www.proquest.com/docview/2543896230?pq-origsite=%requestingapplication%
PQID 2543896230
PQPubID 2034790
PageCount 35
ParticipantIDs doaj_primary_oai_doaj_org_article_f61ddd109d6e4e9ab8a86431b0d8a606
proquest_journals_2543896230
crossref_citationtrail_10_1186_s12645_021_00085_9
crossref_primary_10_1186_s12645_021_00085_9
springer_journals_10_1186_s12645_021_00085_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-01
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-01
  day: 01
PublicationDecade 2020
PublicationPlace Vienna
PublicationPlace_xml – name: Vienna
– name: Heidelberg
PublicationSubtitle Basic,Translational and Clinical Research
PublicationTitle Cancer nanotechnology
PublicationTitleAbbrev Cancer Nano
PublicationYear 2021
Publisher Springer Vienna
Springer Nature B.V
BMC
Publisher_xml – name: Springer Vienna
– name: Springer Nature B.V
– name: BMC
References Nasseri (CR65) 2005; 300
Jemal, Bray, Center, Ferlay, Ward, Forman (CR43) 2011; 61
Benachir, Lafleur (CR15) 1996; 70
Moghaddam, Hamedi, Dezfulian (CR60) 2016; 25
Soman, Baldwin, Hu, Marsh, Lanza, Heuser (CR87) 2009; 119
Vogel, Jähnig (CR90) 1986; 50
Aleskandarany, Soria, Green, Nolan, Diez-Rodriguez, Ellis (CR6) 2015; 151
DeGrado, Musso, Lieber, Kaiser, Kezdy (CR24) 1982; 37
Naderinezhad, Amoabediny, Haghiralsadat (CR63) 2017; 7
Sharon, Oren, Shai, Anglister (CR81) 1999; 38
Baillie, Florence, Hume, Muirhead, Rogerson (CR9) 1985; 37
Bello, Bello, Granados (CR14) 1982; 21
Reddy, Padman, Santosh (CR75) 2012; 3
Moghaddam, Mortazavi, Hamedi, Nabiuni, Roodbari (CR61) 2020; 20
Jallouk, Palekar, Marsh, Pan, Pham, Schlesinger (CR40) 2015; 26
Bouchalova, Kharaishvili, Bouchal, Vrbkova, Megova, Hlobilkova (CR16) 2014; 15
Jamasbi, Mularski, Separovic (CR41) 2016; 16
Shirzad, Jamehbozorgi, Akbarzadeh, Aghabozorg (CR84) 2019; 17
Li, Tang, Zhang, Lv, Li, Chen (CR53) 2018; 18
van Sorge, Wijnen, van Delft, Coré-Bodelier, van Haeringen (CR89) 1999; 21
Liu, Yu, He, Xiao, Wang, Song (CR54) 2008; 47
Pan, Soman, Schlesinger, Lanza, Wickline (CR68) 2011; 3
Schweizer (CR79) 2009; 625
Mao, Liu, Ai, Wang, Wang, Li (CR57) 2017; 10
Akbarzadeh, Shayan, Bourbour, Moghtaderi, Noorbazargan, Eshrati Yeganeh (CR4) 2021; 10
Wan (CR91) 2018; 15
Choi (CR19) 2007; 59
Shi, Li, Li, Zong, Han, Chen (CR82) 2016; 100
Putri, Sutriyo, Saputri (CR72) 2020; 12
Jang, Shin, Lim, Han, Park, Shin (CR42) 2003; 91
Malekzadeh, Derakhshan, Malekzadeh (CR56) 2009; 12
Jo, Park, Kollipara, An, Song, Han (CR44) 2012; 258
Culp, Neal, Massey, Egevad, Pisa, Garland (CR23) 2006; 5
Iochmann, Bléchet, Chabot, Saulnier, Amini, Gaud (CR38) 2009; 26
Ladokhin, Selsted, White (CR49) 1997; 72
Lee, Hung, Chen, Huang (CR52) 2008; 105
Basu, Haldar (CR11) 1998; 4
Cheng, Thapa, Remant, Xu (CR18) 2015; 3
Akbarzadeh, Yaraki, Bourbour, Noorbazargan, Lajevardi, Shilsar (CR3) 2020; 57
Bazzo, Tappin, Pastore, Harvey, Carver, Campbell (CR12) 1988; 173
Moon, Park, Choi, Kim, Lee, Kim (CR62) 2008; 51
Palit, Kar, Sharma, Das (CR67) 2015; 230
Adade, Oliveira, Pais, Souto-Padrón (CR1) 2013; 69
Eisenberg (CR29) 1984; 53
Skalickova, Heger, Krejcova, Pekarik, Bastl, Janda (CR85) 2015; 7
Hait, Grais, Benz, Cadman (CR34) 1985; 14
Xu, Chen, Tsosie, Xie, Li, Wan (CR94) 2016
Park, Choi, Kwak, Oh, Yoon, Han (CR70) 2011; 71
Akbarzadeh (CR2) 2020; 11
Chu, Cheng, Huang, Chang, Chi, Su (CR22) 2007; 80
Choi, Kang, Lee, Bae (CR20) 2014; 35
Misra, Ye, Kim, Pan (CR59) 2015; 10
Qiubo (CR73) 2000; 10
Fan, Hu, Pang, Sun, Wang, Li (CR30) 2014; 9
Yu, Wang, Yan, Wang, Li, Liu (CR96) 2018; 18
Wang, Li, Tan, Peng, Sun, Wang (CR93) 2017; 13
Laprise-Pelletier, Simão, Fortin (CR50) 2018; 7
Kanaani (CR45) 2017; 18
Tosteson, Tosteson (CR88) 1981; 36
Fu, Kao (CR31) 2010; 7
Shad, Karizi, Javan, Mirzaie, Noorbazargan, Akbarzadeh (CR80) 2020; 65
Fu, Tan, Er, Chen, Nesaretnam (CR32) 2016; 11
Hedayati Ch, Abolhassani Targhi, Shamsi, Heidari, Salehi Moghadam, Mirzaie (CR35) 2021; 109
Zhang, Wang, Xu, Miao, Zeng, Cui (CR98) 2014; 229
Yang, Harroun, Weiss, Ding, Huang (CR95) 2001; 81
Zhang, Chen (CR97) 2017; 16
Chou (CR21) 2010; 70
Ryu, Jang, Jo, Kim, Eom, Kim (CR77) 2014; 37
Badria, Fathy, Fatehe, Elimam, Ghazy (CR8) 2017; 2
Wang, Chen, Zhang, Yang, Li, Lü (CR92) 2009; 284
Rady, Siddiqui, Rady, Mukhtar (CR74) 2017; 402
Kumar, Rajeshwarrao (CR48) 2011; 1
Do, Weindl, Grohmann, Salwiczek, Koksch, Korting (CR28) 2014; 23
Mahale, Thakkar, Mali, Walunj, Chaudhari (CR55) 2012; 183
Naji (CR64) 2020
Ip, Liao, Lin, Lin, Yang, Lin (CR39) 2008; 22
Barrajón-Catalán, Menéndez-Gutiérrez, Falco, Carrato, Saceda, Micol (CR10) 2010; 290
Saini, Chopra, Peterson (CR78) 1999; 37
Shin, Jeong, Cho, Park, Chung, Lee (CR83) 2013; 8
Amini (CR7) 2015; 4
Callagy, Pharoah, Pinder, Hsu, Nielsen, Ragaz (CR17) 2006; 12
Meuten (CR58) 2002
Deng, Sriwiriyajan, Tedasen, Hiransai (CR27) 2016; 188
Hematyar, Soleimani, Es-Haghi, Rezaei Mokarram (CR36) 2018; 46
Lee, Chen, Huang (CR51) 2004; 43
Deljoo, Rabiee, Rabiee (CR25) 2019; 2
Pulaski, Ostrand-Rosenberg (CR71) 2000; 39
Hernandez-Aya, Gonzalez-Angulo (CR37) 2013; 93
Kubo, Loegering, Adolphson, Gleich (CR47) 1999; 118
Soman, Lanza, Heuser, Schlesinger, Wickline (CR86) 2008; 8
Park, Jeong, Park, Cho, Chung, Min (CR69) 2010; 29
Rinaldi, Del Favero, Rondelli, Pieretti, Bogni, Ponti (CR76) 2017; 32
Bechinger (CR13) 1997; 156
Dempsey (CR26) 1990; 1031
Kontoyannis, Sweetland (CR46) 2007; 25
Oršolić (CR66) 2012; 31
Zhu, Wang, Wang, Zhang (CR99) 2000; 16
Alemi, Reza, Haghiralsadat, Jaliani, Karamallah, Hosseini (CR5) 2018; 16
Ghafelehbashi, Akbarzadeh, Yaraki, Lajevardi, Fatemizadeh (CR33) 2019; 569
FD Moghaddam (85_CR61) 2020; 20
F Rinaldi (85_CR76) 2017; 32
Q Fan (85_CR30) 2014; 9
K Bouchalova (85_CR16) 2014; 15
CM Adade (85_CR1) 2013; 69
A Baillie (85_CR9) 1985; 37
KM Naji (85_CR64) 2020
W Qiubo (85_CR73) 2000; 10
W Shi (85_CR82) 2016; 100
M Hedayati Ch (85_CR35) 2021; 109
F Schweizer (85_CR79) 2009; 625
E Amini (85_CR7) 2015; 4
WD Culp (85_CR23) 2006; 5
M-H Jang (85_CR42) 2003; 91
DJ Meuten (85_CR58) 2002
D Eisenberg (85_CR29) 1984; 53
J Mao (85_CR57) 2017; 10
L Wan (85_CR91) 2018; 15
S Iochmann (85_CR38) 2009; 26
M Laprise-Pelletier (85_CR50) 2018; 7
JE Choi (85_CR20) 2014; 35
M Sharon (85_CR81) 1999; 38
MA Aleskandarany (85_CR6) 2015; 151
I Rady (85_CR74) 2017; 402
JS Ryu (85_CR77) 2014; 37
M Li (85_CR53) 2018; 18
BA Pulaski (85_CR71) 2000; 39
E Jamasbi (85_CR41) 2016; 16
S Palit (85_CR67) 2015; 230
W DeGrado (85_CR24) 1982; 37
A Jemal (85_CR43) 2011; 61
C Wang (85_CR92) 2009; 284
J Bello (85_CR14) 1982; 21
R Bazzo (85_CR12) 1988; 173
SS Saini (85_CR78) 1999; 37
J-Y Fu (85_CR32) 2016; 11
NR Soman (85_CR87) 2009; 119
N Do (85_CR28) 2014; 23
N Oršolić (85_CR66) 2012; 31
L Kanaani (85_CR45) 2017; 18
B Cheng (85_CR18) 2015; 3
X Zhu (85_CR99) 2000; 16
Y Deng (85_CR27) 2016; 188
A Kontoyannis (85_CR46) 2007; 25
S Liu (85_CR54) 2008; 47
R Ghafelehbashi (85_CR33) 2019; 569
A Basu (85_CR11) 1998; 4
B Nasseri (85_CR65) 2005; 300
T-C Chou (85_CR21) 2010; 70
S Deljoo (85_CR25) 2019; 2
S-T Chu (85_CR22) 2007; 80
M Jo (85_CR44) 2012; 258
CH Dempsey (85_CR26) 1990; 1031
SK Misra (85_CR59) 2015; 10
GM Callagy (85_CR17) 2006; 12
EJ Choi (85_CR19) 2007; 59
I Akbarzadeh (85_CR4) 2021; 10
F Badria (85_CR8) 2017; 2
DA Putri (85_CR72) 2020; 12
A Alemi (85_CR5) 2018; 16
E Barrajón-Catalán (85_CR10) 2010; 290
JH Park (85_CR69) 2010; 29
Y Yu (85_CR96) 2018; 18
W Zhang (85_CR98) 2014; 229
NR Soman (85_CR86) 2008; 8
GP Kumar (85_CR48) 2011; 1
M Hematyar (85_CR36) 2018; 46
T Benachir (85_CR15) 1996; 70
SF Zhang (85_CR97) 2017; 16
Y Fu (85_CR31) 2010; 7
R Malekzadeh (85_CR56) 2009; 12
AS Ladokhin (85_CR49) 1997; 72
I Akbarzadeh (85_CR3) 2020; 57
H Vogel (85_CR90) 1986; 50
L Yang (85_CR95) 2001; 81
AP Jallouk (85_CR40) 2015; 26
S Naderinezhad (85_CR63) 2017; 7
MT Lee (85_CR52) 2008; 105
H Kubo (85_CR47) 1999; 118
J-M Shin (85_CR83) 2013; 8
LF Hernandez-Aya (85_CR37) 2013; 93
N Mahale (85_CR55) 2012; 183
WN Hait (85_CR34) 1985; 14
PM Shad (85_CR80) 2020; 65
M Shirzad (85_CR84) 2019; 17
I Akbarzadeh (85_CR2) 2020; 11
MH Park (85_CR70) 2011; 71
S Skalickova (85_CR85) 2015; 7
BS Reddy (85_CR75) 2012; 3
AA van Sorge (85_CR89) 1999; 21
Y-Q Xu (85_CR94) 2016
FD Moghaddam (85_CR60) 2016; 25
J Wang (85_CR93) 2017; 13
S-W Ip (85_CR39) 2008; 22
D-O Moon (85_CR62) 2008; 51
M Tosteson (85_CR88) 1981; 36
H Pan (85_CR68) 2011; 3
B Bechinger (85_CR13) 1997; 156
M-T Lee (85_CR51) 2004; 43
References_xml – volume: 1
  start-page: 208
  issue: 4
  year: 2011
  end-page: 219
  ident: CR48
  article-title: Nonionic surfactant vesicular systems for effective drug delivery—an overview
  publication-title: Acta Pharmaceutica Sinica B
  doi: 10.1016/j.apsb.2011.09.002
– volume: 16
  start-page: 40
  issue: 1
  year: 2016
  end-page: 45
  ident: CR41
  article-title: Model membrane and cell studies of antimicrobial activity of melittin analogues
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026615666150703115919
– volume: 37
  start-page: 329
  issue: 1
  year: 1982
  end-page: 338
  ident: CR24
  article-title: Kinetics and mechanism of hemolysis induced by melittin and by a synthetic melittin analogue
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(82)84681-X
– volume: 22
  start-page: 237
  issue: 2
  year: 2008
  end-page: 245
  ident: CR39
  article-title: The role of mitochondria in bee venom-induced apoptosis in human breast cancer MCF7 cells
  publication-title: Vivo
– volume: 21
  start-page: 461
  issue: 3
  year: 1982
  end-page: 465
  ident: CR14
  article-title: Conformation and aggregation of melittin: dependence of pH and concentration
  publication-title: Biochemistry
  doi: 10.1021/bi00532a007
– volume: 20
  start-page: 790
  issue: 7
  year: 2020
  end-page: 799
  ident: CR61
  article-title: Apoptotic effects of melittin on 4T1 breast cancer cell line is associated with up regulation of Mfn1 and Drp1 mRNA expression
  publication-title: Anti-Cancer Agents Med Chem
  doi: 10.2174/1871520620666200211091451
– volume: 16
  start-page: 1
  issue: 1
  year: 2018
  end-page: 20
  ident: CR5
  article-title: Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-018-0351-4
– volume: 109
  start-page: 966
  issue: 6
  year: 2021
  end-page: 980
  ident: CR35
  article-title: Niosome‐encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug‐resistant clinical strains of Pseudomonas aeruginosa
  publication-title: J Biomed Mater Res A
  doi: 10.1002/jbm.a.37086
– volume: 230
  start-page: 1729
  issue: 8
  year: 2015
  end-page: 1739
  ident: CR67
  article-title: Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ROS and activation of ASK1/JNK pathway
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.24818
– volume: 25
  start-page: 947
  issue: 5
  year: 2016
  end-page: 952
  ident: CR60
  article-title: Anti-tumor effect of C-phycocyanin from sp. ISC55 in inbred BALB/c mice injected with 4T1 breast cancer cell
  publication-title: Comp Clin Pathol
  doi: 10.1007/s00580-016-2285-2
– volume: 72
  start-page: 1762
  issue: 4
  year: 1997
  end-page: 1766
  ident: CR49
  article-title: Sizing membrane pores in lipid vesicles by leakage of co-encapsulated markers: pore formation by melittin
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(97)78822-2
– volume: 300
  start-page: 95
  issue: 1–2
  year: 2005
  end-page: 101
  ident: CR65
  article-title: Effect of cholesterol and temperature on the elastic properties of niosomal membranes
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2005.05.009
– volume: 10
  start-page: 542
  year: 2000
  end-page: 544
  ident: CR73
  article-title: Study on the immune-regulating mechanism of the bee venom
  publication-title: Chin J Immunol
– volume: 37
  start-page: 1605
  issue: 11
  year: 1999
  end-page: 1619
  ident: CR78
  article-title: Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells
  publication-title: Toxicon
  doi: 10.1016/S0041-0101(99)00110-5
– volume: 70
  start-page: 440
  issue: 2
  year: 2010
  end-page: 446
  ident: CR21
  article-title: Drug combination studies and their synergy quantification using the Chou-Talalay method
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-09-1947
– volume: 18
  start-page: 365
  issue: 2
  year: 2017
  ident: CR45
  article-title: Effects of cisplatin-loaded niosomal nanoparticleson BT-20 human breast carcinoma cells
  publication-title: Asian Pac J Cancer Prev
– volume: 36
  start-page: 109
  issue: 1
  year: 1981
  end-page: 116
  ident: CR88
  article-title: Melittin forms channels in lipid bilayers
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(81)84719-4
– volume: 4
  start-page: 1099
  issue: 12
  year: 1998
  end-page: 1109
  ident: CR11
  article-title: The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death
  publication-title: Mol Hum Reprod
  doi: 10.1093/molehr/4.12.1099
– volume: 93
  start-page: 473
  issue: 2
  year: 2013
  end-page: 491
  ident: CR37
  article-title: Adjuvant systemic therapies in breast cancer
  publication-title: Surg Clin North Am
  doi: 10.1016/j.suc.2012.12.002
– volume: 59
  start-page: 115
  issue: 1
  year: 2007
  end-page: 119
  ident: CR19
  article-title: Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21
  publication-title: Nutr Cancer
  doi: 10.1080/01635580701419030
– volume: 10
  start-page: 71
  issue: 1
  year: 2017
  ident: CR57
  article-title: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0442-y
– volume: 69
  start-page: 227
  year: 2013
  end-page: 239
  ident: CR1
  article-title: Melittin peptide kills Trypanosoma cruzi parasites by inducing different cell death pathways
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2013.03.011
– volume: 53
  start-page: 595
  issue: 1
  year: 1984
  end-page: 623
  ident: CR29
  article-title: Three-dimensional structure of membrane and surface proteins
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.bi.53.070184.003115
– year: 2020
  ident: CR64
  article-title: Hepatoprotective activity of melittin on isoniazid and rifampicin induced liver damage in male albino rats
  publication-title: BioRxiv
  doi: 10.1101/2020.09.08.287094
– volume: 3
  start-page: 318
  issue: 3
  year: 2011
  end-page: 327
  ident: CR68
  article-title: Cytolytic peptide nanoparticles (‘NanoBees’) for cancer therapy
  publication-title: Nanomed Nanobiotechnol
  doi: 10.1002/wnan.126
– volume: 4
  start-page: 68
  issue: 2
  year: 2015
  end-page: 73
  ident: CR7
  article-title: Cytotoxic and pro-apoptotic effects of honey bee venom and chrysin on human ovarian cancer cells
  publication-title: Asia Pac J Med Toxicol
– volume: 46
  start-page: S1226
  issue: sup3
  year: 2018
  end-page: S1235
  ident: CR36
  article-title: Synergistic co-delivery of doxorubicin and melittin using functionalized magnetic nanoparticles for cancer treatment: loading and in vitro release study by LC–MS/MS
  publication-title: Artif Cells Nanomed Biotechnol
  doi: 10.1080/21691401.2018.1536063
– volume: 38
  start-page: 15305
  issue: 46
  year: 1999
  end-page: 15316
  ident: CR81
  article-title: 2D-NMR and ATR-FTIR study of the structure of a cell-selective diastereomer of melittin and its orientation in phospholipids
  publication-title: Biochemistry
  doi: 10.1021/bi991225t
– volume: 100
  start-page: 5059
  issue: 11
  year: 2016
  end-page: 5067
  ident: CR82
  article-title: Antimicrobial peptide melittin against Xanthomonas oryzae pv oryzae, the bacterial leaf blight pathogen in rice
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-016-7400-4
– volume: 80
  start-page: 364
  issue: 4
  year: 2007
  end-page: 369
  ident: CR22
  article-title: Phospholipase A2-independent Ca2+ entry and subsequent apoptosis induced by melittin in human MG63 osteosarcoma cells
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2006.09.024
– volume: 65
  start-page: 104756
  year: 2020
  ident: CR80
  article-title: Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line)
  publication-title: Toxicol in Vitro
  doi: 10.1016/j.tiv.2019.104756
– volume: 13
  start-page: 599
  issue: 2
  year: 2017
  end-page: 604
  ident: CR93
  article-title: Melittin inhibits the invasion of MCF-7 cells by downregulating CD147 and MMP-9 expression
  publication-title: Oncol Lett
  doi: 10.3892/ol.2016.5516
– volume: 119
  start-page: 2830
  issue: 9
  year: 2009
  end-page: 2842
  ident: CR87
  article-title: Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth
  publication-title: J Clin Investig
  doi: 10.1172/JCI38842
– volume: 183
  start-page: 46
  year: 2012
  end-page: 54
  ident: CR55
  article-title: Niosomes: novel sustained release nonionic stable vesicular systems—an overview
  publication-title: Adv Coll Interface Sci
  doi: 10.1016/j.cis.2012.08.002
– volume: 23
  start-page: 326
  issue: 5
  year: 2014
  end-page: 331
  ident: CR28
  article-title: Cationic membrane-active peptides–anticancer and antifungal activity as well as penetration into human skin
  publication-title: Exp Dermatol
  doi: 10.1111/exd.12384
– volume: 173
  start-page: 139
  issue: 1
  year: 1988
  end-page: 146
  ident: CR12
  article-title: The structure of melittin. A 1H-NMR study in methanol
  publication-title: Eur J Biochem
  doi: 10.1111/j.1432-1033.1988.tb13977.x
– volume: 37
  start-page: 239
  issue: 2
  year: 2014
  end-page: 244
  ident: CR77
  article-title: The effect of acteoside on intracellular Ca 2+ mobilization and phospholipase C activity in RBL-2H3 cells stimulated by melittin
  publication-title: Arch Pharmacal Res
  doi: 10.1007/s12272-013-0208-1
– volume: 32
  start-page: 538
  issue: 1
  year: 2017
  end-page: 546
  ident: CR76
  article-title: pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain in murine models
  publication-title: J Enzyme Inhib Med Chem
  doi: 10.1080/14756366.2016.1268607
– volume: 10
  start-page: 173
  issue: 3
  year: 2021
  ident: CR4
  article-title: Preparation, Optimization and In-Vitro Evaluation of Curcumin-Loaded Niosome@ calcium alginate nanocarrier as a new approach for breast cancer treatment
  publication-title: Biology
  doi: 10.3390/biology10030173
– volume: 151
  start-page: 325
  issue: 2
  year: 2015
  end-page: 333
  ident: CR6
  article-title: Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-015-3406-3
– volume: 18
  start-page: 383
  issue: 1
  year: 2018
  ident: CR96
  article-title: Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-4230-z
– volume: 625
  start-page: 190
  issue: 1–3
  year: 2009
  end-page: 194
  ident: CR79
  article-title: Cationic amphiphilic peptides with cancer-selective toxicity
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2009.08.043
– volume: 15
  start-page: 1166
  issue: 12
  year: 2014
  end-page: 1175
  ident: CR16
  article-title: Triple negative breast cancer-BCL2 in prognosis and prediction
  publication-title: Rev Curr Drug Targets
  doi: 10.2174/1389450115666141106151143
– volume: 8
  start-page: e69380
  issue: 7
  year: 2013
  ident: CR83
  article-title: Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0069380
– volume: 16
  start-page: 24
  year: 2000
  end-page: 25
  ident: CR99
  article-title: Immunomodulatory effects of bee venom on S180 sarcoma mice
  publication-title: Pharmacol Clin Chin Materia Medica
– volume: 7
  start-page: 429
  issue: 4
  year: 2010
  end-page: 444
  ident: CR31
  article-title: Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems
  publication-title: Expert Opin Drug Deliv
  doi: 10.1517/17425241003602259
– volume: 35
  start-page: 12255
  issue: 12
  year: 2014
  end-page: 12263
  ident: CR20
  article-title: Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy
  publication-title: Tumor Biol
  doi: 10.1007/s13277-014-2534-4
– volume: 7
  start-page: 1701460
  issue: 16
  year: 2018
  ident: CR50
  article-title: Gold nanoparticles in radiotherapy and recent progress in nanobrachytherapy
  publication-title: Adv Healthcare Mater
  doi: 10.1002/adhm.201701460
– volume: 29
  start-page: 209
  issue: 2
  year: 2010
  end-page: 215
  ident: CR69
  article-title: Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-κB and AP-1-dependent MMP-9 expression
  publication-title: Mol Cells
  doi: 10.1007/s10059-010-0028-9
– volume: 188
  start-page: 87
  year: 2016
  end-page: 95
  ident: CR27
  article-title: Graidist P (2016) Anti-cancer effects of Piper nigrum via inducing multiple molecular signaling in vivo and in vitro
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2016.04.047
– volume: 26
  start-page: 1640
  issue: 8
  year: 2015
  end-page: 1650
  ident: CR40
  article-title: Delivery of a protease-activated cytolytic peptide prodrug by perfluorocarbon nanoparticles
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.5b00246
– volume: 43
  start-page: 3590
  issue: 12
  year: 2004
  end-page: 3599
  ident: CR51
  article-title: Energetics of pore formation induced by membrane active peptides
  publication-title: Biochemistry
  doi: 10.1021/bi036153r
– volume: 12
  start-page: 113
  issue: 4
  year: 2020
  end-page: 118
  ident: CR72
  article-title: Cellular uptake study and cytotoxicity study of resveratrol-gold-peg-folate (RSVAU-PEG-FA) nanoparticles on hela human cervical cancer cell line
  publication-title: Int J Appl Pharm
  doi: 10.22159/ijap.2020v12i4.37307
– volume: 71
  start-page: 801
  issue: 8
  year: 2011
  end-page: 812
  ident: CR70
  article-title: Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB
  publication-title: Prostate
  doi: 10.1002/pros.21296
– volume: 51
  start-page: 112
  issue: 1
  year: 2008
  end-page: 120
  ident: CR62
  article-title: Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2007.08.015
– volume: 402
  start-page: 16
  year: 2017
  end-page: 31
  ident: CR74
  article-title: Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.05.010
– volume: 105
  start-page: 5087
  issue: 13
  year: 2008
  end-page: 5092
  ident: CR52
  article-title: Mechanism and kinetics of pore formation in membranes by water-soluble amphipathic peptides
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0710625105
– volume: 11
  start-page: 2
  year: 2020
  ident: CR2
  article-title: Niosomal Formulation for Co-Administration of Hydrophobic Anticancer Drugs into MCF-7 Cancer Cells
  publication-title: Arch Adv Biosci
– volume: 3
  start-page: 25
  issue: 1
  year: 2015
  end-page: 29
  ident: CR18
  article-title: Dual secured nano-melittin for the safe and effective eradication of cancer cells
  publication-title: J Mater Chem B
  doi: 10.1039/C4TB01401D
– volume: 2
  start-page: 66
  issue: 1
  year: 2019
  end-page: 91
  ident: CR25
  article-title: Curcumin-hybrid nanoparticles in drug delivery system
  publication-title: Asian J Nanosci Mater
– volume: 284
  start-page: 3804
  issue: 6
  year: 2009
  end-page: 3813
  ident: CR92
  article-title: Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IκBα kinase-NFκB
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M807191200
– volume: 81
  start-page: 1475
  issue: 3
  year: 2001
  end-page: 1485
  ident: CR95
  article-title: Barrel-stave model or toroidal model? A case study on melittin pores
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(01)75802-X
– volume: 17
  start-page: 231
  issue: 5
  year: 2019
  end-page: 239
  ident: CR84
  article-title: The role of polyethylene glycol size in chemical spectra, cytotoxicity, and release of PEGylated nanoliposomal cisplatin
  publication-title: Assay Drug Dev Technol
  doi: 10.1089/adt.2019.923
– volume: 26
  start-page: 457
  issue: 5
  year: 2009
  end-page: 467
  ident: CR38
  article-title: Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion
  publication-title: Clin Exp Metas
  doi: 10.1007/s10585-009-9245-z
– volume: 37
  start-page: 863
  issue: 12
  year: 1985
  end-page: 868
  ident: CR9
  article-title: The preparation and properties of niosomes—non-ionic surfactant vesicles
  publication-title: J Pharm Pharmacol
  doi: 10.1111/j.2042-7158.1985.tb04990.x
– volume: 9
  start-page: 1365
  issue: 4
  year: 2014
  end-page: 1370
  ident: CR30
  article-title: Melittin protein inhibits the proliferation of MG63 cells by activating inositol-requiring protein-1α and X-box binding protein 1-mediated apoptosis
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.1936
– volume: 118
  start-page: 426
  issue: 2–4
  year: 1999
  end-page: 428
  ident: CR47
  article-title: Cytotoxic properties of eosinophil granule major basic protein for tumor cells
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000024154
– volume: 2
  start-page: 1
  issue: 1
  year: 2017
  end-page: 4
  ident: CR8
  article-title: Evaluate the cytotoxic activity of honey, propolis, and bee venom from different localities in Egypt against liver, breast, and colorectal cancer
  publication-title: J Apither
  doi: 10.5455/ja.20170203075953
– volume: 18
  start-page: 132
  year: 2018
  end-page: 143
  ident: CR53
  article-title: Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2015.02.022
– volume: 569
  start-page: 118580
  year: 2019
  ident: CR33
  article-title: Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2019.118580
– volume: 25
  start-page: 272
  issue: 6
  year: 2007
  end-page: 275
  ident: CR46
  article-title: Adjuvant therapy for breast cancer
  publication-title: Surg Infect (larchmt)
– volume: 258
  start-page: 72
  issue: 1
  year: 2012
  end-page: 81
  ident: CR44
  article-title: Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2011.10.009
– volume: 57
  start-page: 101715
  year: 2020
  ident: CR3
  article-title: Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: an in-vitro investigation
  publication-title: J Drug Del Sci Technol
  doi: 10.1016/j.jddst.2020.101715
– volume: 21
  start-page: 91
  issue: 2
  year: 1999
  end-page: 95
  ident: CR89
  article-title: Flurbiprofen, S (+), eyedrops: formulation, enantiomeric assay, shelflife and pharmacology
  publication-title: Pharm World Sci
  doi: 10.1023/A:1008609513880
– volume: 47
  start-page: 1964
  issue: 6
  year: 2008
  end-page: 1973
  ident: CR54
  article-title: Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway
  publication-title: Hepatology
  doi: 10.1002/hep.22240
– volume: 5
  start-page: 1332
  issue: 6
  year: 2006
  end-page: 1343
  ident: CR23
  article-title: Proteomic analysis of tumor establishment and growth in the B16–F10 mouse melanoma model
  publication-title: J Proteome Res
  doi: 10.1021/pr060059q
– volume: 14
  start-page: 202
  issue: 3
  year: 1985
  end-page: 205
  ident: CR34
  article-title: Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00258116
– volume: 229
  start-page: 118
  issue: 1
  year: 2014
  end-page: 125
  ident: CR98
  article-title: Perfluorooctanoic acid stimulates breast cancer cells invasion and up-regulates matrix metalloproteinase-2/-9 expression mediated by activating NF-κB
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2014.06.004
– volume: 39
  start-page: 202
  issue: 1
  year: 2000
  ident: CR71
  article-title: Mouse 4T1 breast tumor model
  publication-title: Curr Protoc Immunol
– volume: 3
  start-page: 1560
  issue: 6
  year: 2012
  ident: CR75
  article-title: Niosomes as nanocarrier systems: a review
  publication-title: Int J Pharm Sci Res
– volume: 7
  start-page: 5428
  issue: 10
  year: 2015
  end-page: 5442
  ident: CR85
  article-title: Perspective of use of antiviral peptides against influenza virus
  publication-title: Viruses
  doi: 10.3390/v7102883
– volume: 8
  start-page: 1131
  issue: 4
  year: 2008
  end-page: 1136
  ident: CR86
  article-title: Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides
  publication-title: Nano Lett
  doi: 10.1021/nl073290r
– volume: 16
  start-page: 3581
  issue: 3
  year: 2017
  end-page: 3586
  ident: CR97
  article-title: Melittin exerts an antitumor effect on non-small cell lung cancer cells
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2017.6970
– volume: 12
  start-page: 2468
  issue: 8
  year: 2006
  end-page: 2475
  ident: CR17
  article-title: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2719
– volume: 61
  start-page: 69
  issue: 2
  year: 2011
  end-page: 90
  ident: CR43
  article-title: Global cancer statistics
  publication-title: CA
– volume: 10
  start-page: e0125908
  issue: 6
  year: 2015
  ident: CR59
  article-title: Defined nanoscale chemistry influences delivery of peptido-toxins for cancer therapy
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0125908
– volume: 290
  start-page: 192
  issue: 2
  year: 2010
  end-page: 203
  ident: CR10
  article-title: Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2009.09.010
– volume: 15
  start-page: 1271
  issue: 1
  year: 2018
  end-page: 1278
  ident: CR91
  article-title: TT-1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl-2 and Bax
  publication-title: Oncol Lett
– volume: 70
  start-page: 831
  issue: 2
  year: 1996
  end-page: 840
  ident: CR15
  article-title: Osmotic and pH transmembrane gradients control the lytic power of melittin
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(96)79622-4
– volume: 7
  start-page: 30008
  issue: 48
  year: 2017
  end-page: 30019
  ident: CR63
  article-title: Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers
  publication-title: RSC Adv
  doi: 10.1039/C7RA01736G
– volume: 1031
  start-page: 143
  issue: 2
  year: 1990
  end-page: 161
  ident: CR26
  article-title: The actions of melittin on membranes
  publication-title: Biochem Biophys Acta
– volume: 12
  start-page: 576
  issue: 6
  year: 2009
  end-page: 583
  ident: CR56
  article-title: Gastric Cancer in Iran
  publication-title: Epidemiol Risk Fact
– year: 2002
  ident: CR58
  article-title: Diagnostic schemes and algorithms
  publication-title: Tum Domes Anim.
  doi: 10.1002/9781119181200
– volume: 50
  start-page: 573
  issue: 4
  year: 1986
  end-page: 582
  ident: CR90
  article-title: The structure of melittin in membranes
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(86)83497-X
– volume: 91
  start-page: 95
  issue: 2
  year: 2003
  end-page: 104
  ident: CR42
  article-title: Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.91.95
– volume: 31
  start-page: 173
  issue: 1–2
  year: 2012
  end-page: 194
  ident: CR66
  article-title: Bee venom in cancer therapy
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-011-9339-3
– year: 2016
  ident: CR94
  article-title: Niosome encapsulation of curcumin: characterization and cytotoxic effect on ovarian cancer cells
  publication-title: J Nanomater
  doi: 10.1155/2016/6365295
– volume: 156
  start-page: 197
  issue: 3
  year: 1997
  end-page: 211
  ident: CR13
  article-title: Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin
  publication-title: J Membr Biol
  doi: 10.1007/s002329900201
– volume: 11
  start-page: 79
  year: 2016
  end-page: 80
  ident: CR32
  article-title: Tumor-targeted niosome as novel carrier for intravenous administration of tocotrienol
  publication-title: Asian J Pharm Sci
  doi: 10.1016/j.ajps.2015.10.062
– volume: 300
  start-page: 95
  issue: 1–2
  year: 2005
  ident: 85_CR65
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2005.05.009
– volume: 7
  start-page: 30008
  issue: 48
  year: 2017
  ident: 85_CR63
  publication-title: RSC Adv
  doi: 10.1039/C7RA01736G
– volume: 13
  start-page: 599
  issue: 2
  year: 2017
  ident: 85_CR93
  publication-title: Oncol Lett
  doi: 10.3892/ol.2016.5516
– volume: 188
  start-page: 87
  year: 2016
  ident: 85_CR27
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2016.04.047
– volume: 53
  start-page: 595
  issue: 1
  year: 1984
  ident: 85_CR29
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.bi.53.070184.003115
– volume: 10
  start-page: 542
  year: 2000
  ident: 85_CR73
  publication-title: Chin J Immunol
– volume: 7
  start-page: 1701460
  issue: 16
  year: 2018
  ident: 85_CR50
  publication-title: Adv Healthcare Mater
  doi: 10.1002/adhm.201701460
– volume: 25
  start-page: 272
  issue: 6
  year: 2007
  ident: 85_CR46
  publication-title: Surg Infect (larchmt)
– volume: 10
  start-page: e0125908
  issue: 6
  year: 2015
  ident: 85_CR59
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0125908
– volume: 7
  start-page: 429
  issue: 4
  year: 2010
  ident: 85_CR31
  publication-title: Expert Opin Drug Deliv
  doi: 10.1517/17425241003602259
– volume: 100
  start-page: 5059
  issue: 11
  year: 2016
  ident: 85_CR82
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-016-7400-4
– volume: 22
  start-page: 237
  issue: 2
  year: 2008
  ident: 85_CR39
  publication-title: Vivo
– volume: 43
  start-page: 3590
  issue: 12
  year: 2004
  ident: 85_CR51
  publication-title: Biochemistry
  doi: 10.1021/bi036153r
– volume: 105
  start-page: 5087
  issue: 13
  year: 2008
  ident: 85_CR52
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0710625105
– volume: 47
  start-page: 1964
  issue: 6
  year: 2008
  ident: 85_CR54
  publication-title: Hepatology
  doi: 10.1002/hep.22240
– volume: 4
  start-page: 1099
  issue: 12
  year: 1998
  ident: 85_CR11
  publication-title: Mol Hum Reprod
  doi: 10.1093/molehr/4.12.1099
– volume: 9
  start-page: 1365
  issue: 4
  year: 2014
  ident: 85_CR30
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.1936
– volume: 16
  start-page: 40
  issue: 1
  year: 2016
  ident: 85_CR41
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026615666150703115919
– volume: 37
  start-page: 239
  issue: 2
  year: 2014
  ident: 85_CR77
  publication-title: Arch Pharmacal Res
  doi: 10.1007/s12272-013-0208-1
– volume: 11
  start-page: 2
  year: 2020
  ident: 85_CR2
  publication-title: Arch Adv Biosci
– volume: 70
  start-page: 831
  issue: 2
  year: 1996
  ident: 85_CR15
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(96)79622-4
– volume: 31
  start-page: 173
  issue: 1–2
  year: 2012
  ident: 85_CR66
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-011-9339-3
– volume: 7
  start-page: 5428
  issue: 10
  year: 2015
  ident: 85_CR85
  publication-title: Viruses
  doi: 10.3390/v7102883
– volume: 290
  start-page: 192
  issue: 2
  year: 2010
  ident: 85_CR10
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2009.09.010
– volume: 8
  start-page: e69380
  issue: 7
  year: 2013
  ident: 85_CR83
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0069380
– volume: 569
  start-page: 118580
  year: 2019
  ident: 85_CR33
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2019.118580
– volume: 20
  start-page: 790
  issue: 7
  year: 2020
  ident: 85_CR61
  publication-title: Anti-Cancer Agents Med Chem
  doi: 10.2174/1871520620666200211091451
– volume: 51
  start-page: 112
  issue: 1
  year: 2008
  ident: 85_CR62
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2007.08.015
– volume: 25
  start-page: 947
  issue: 5
  year: 2016
  ident: 85_CR60
  publication-title: Comp Clin Pathol
  doi: 10.1007/s00580-016-2285-2
– volume: 72
  start-page: 1762
  issue: 4
  year: 1997
  ident: 85_CR49
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(97)78822-2
– volume: 29
  start-page: 209
  issue: 2
  year: 2010
  ident: 85_CR69
  publication-title: Mol Cells
  doi: 10.1007/s10059-010-0028-9
– year: 2016
  ident: 85_CR94
  publication-title: J Nanomater
  doi: 10.1155/2016/6365295
– volume: 12
  start-page: 576
  issue: 6
  year: 2009
  ident: 85_CR56
  publication-title: Epidemiol Risk Fact
– volume: 46
  start-page: S1226
  issue: sup3
  year: 2018
  ident: 85_CR36
  publication-title: Artif Cells Nanomed Biotechnol
  doi: 10.1080/21691401.2018.1536063
– volume: 38
  start-page: 15305
  issue: 46
  year: 1999
  ident: 85_CR81
  publication-title: Biochemistry
  doi: 10.1021/bi991225t
– volume: 16
  start-page: 1
  issue: 1
  year: 2018
  ident: 85_CR5
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-018-0351-4
– volume: 14
  start-page: 202
  issue: 3
  year: 1985
  ident: 85_CR34
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/BF00258116
– volume: 37
  start-page: 1605
  issue: 11
  year: 1999
  ident: 85_CR78
  publication-title: Toxicon
  doi: 10.1016/S0041-0101(99)00110-5
– volume: 71
  start-page: 801
  issue: 8
  year: 2011
  ident: 85_CR70
  publication-title: Prostate
  doi: 10.1002/pros.21296
– volume: 21
  start-page: 461
  issue: 3
  year: 1982
  ident: 85_CR14
  publication-title: Biochemistry
  doi: 10.1021/bi00532a007
– volume: 11
  start-page: 79
  year: 2016
  ident: 85_CR32
  publication-title: Asian J Pharm Sci
  doi: 10.1016/j.ajps.2015.10.062
– volume: 4
  start-page: 68
  issue: 2
  year: 2015
  ident: 85_CR7
  publication-title: Asia Pac J Med Toxicol
– volume: 3
  start-page: 1560
  issue: 6
  year: 2012
  ident: 85_CR75
  publication-title: Int J Pharm Sci Res
– volume: 229
  start-page: 118
  issue: 1
  year: 2014
  ident: 85_CR98
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2014.06.004
– year: 2002
  ident: 85_CR58
  publication-title: Tum Domes Anim.
  doi: 10.1002/9781119181200
– volume: 18
  start-page: 383
  issue: 1
  year: 2018
  ident: 85_CR96
  publication-title: BMC Cancer
  doi: 10.1186/s12885-018-4230-z
– volume: 3
  start-page: 318
  issue: 3
  year: 2011
  ident: 85_CR68
  publication-title: Nanomed Nanobiotechnol
  doi: 10.1002/wnan.126
– volume: 12
  start-page: 2468
  issue: 8
  year: 2006
  ident: 85_CR17
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2719
– volume: 21
  start-page: 91
  issue: 2
  year: 1999
  ident: 85_CR89
  publication-title: Pharm World Sci
  doi: 10.1023/A:1008609513880
– volume: 36
  start-page: 109
  issue: 1
  year: 1981
  ident: 85_CR88
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(81)84719-4
– volume: 39
  start-page: 202
  issue: 1
  year: 2000
  ident: 85_CR71
  publication-title: Curr Protoc Immunol
  doi: 10.1002/0471142735.im2002s39
– volume: 35
  start-page: 12255
  issue: 12
  year: 2014
  ident: 85_CR20
  publication-title: Tumor Biol
  doi: 10.1007/s13277-014-2534-4
– volume: 230
  start-page: 1729
  issue: 8
  year: 2015
  ident: 85_CR67
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.24818
– volume: 32
  start-page: 538
  issue: 1
  year: 2017
  ident: 85_CR76
  publication-title: J Enzyme Inhib Med Chem
  doi: 10.1080/14756366.2016.1268607
– year: 2020
  ident: 85_CR64
  publication-title: BioRxiv
  doi: 10.1101/2020.09.08.287094
– volume: 119
  start-page: 2830
  issue: 9
  year: 2009
  ident: 85_CR87
  publication-title: J Clin Investig
  doi: 10.1172/JCI38842
– volume: 80
  start-page: 364
  issue: 4
  year: 2007
  ident: 85_CR22
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2006.09.024
– volume: 15
  start-page: 1166
  issue: 12
  year: 2014
  ident: 85_CR16
  publication-title: Rev Curr Drug Targets
  doi: 10.2174/1389450115666141106151143
– volume: 70
  start-page: 440
  issue: 2
  year: 2010
  ident: 85_CR21
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-09-1947
– volume: 10
  start-page: 173
  issue: 3
  year: 2021
  ident: 85_CR4
  publication-title: Biology
  doi: 10.3390/biology10030173
– volume: 23
  start-page: 326
  issue: 5
  year: 2014
  ident: 85_CR28
  publication-title: Exp Dermatol
  doi: 10.1111/exd.12384
– volume: 16
  start-page: 3581
  issue: 3
  year: 2017
  ident: 85_CR97
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2017.6970
– volume: 8
  start-page: 1131
  issue: 4
  year: 2008
  ident: 85_CR86
  publication-title: Nano Lett
  doi: 10.1021/nl073290r
– volume: 81
  start-page: 1475
  issue: 3
  year: 2001
  ident: 85_CR95
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(01)75802-X
– volume: 37
  start-page: 863
  issue: 12
  year: 1985
  ident: 85_CR9
  publication-title: J Pharm Pharmacol
  doi: 10.1111/j.2042-7158.1985.tb04990.x
– volume: 18
  start-page: 132
  year: 2018
  ident: 85_CR53
  publication-title: Acta Biomater
  doi: 10.1016/j.actbio.2015.02.022
– volume: 61
  start-page: 69
  issue: 2
  year: 2011
  ident: 85_CR43
  publication-title: CA
– volume: 91
  start-page: 95
  issue: 2
  year: 2003
  ident: 85_CR42
  publication-title: J Pharmacol Sci
  doi: 10.1254/jphs.91.95
– volume: 17
  start-page: 231
  issue: 5
  year: 2019
  ident: 85_CR84
  publication-title: Assay Drug Dev Technol
  doi: 10.1089/adt.2019.923
– volume: 16
  start-page: 24
  year: 2000
  ident: 85_CR99
  publication-title: Pharmacol Clin Chin Materia Medica
– volume: 12
  start-page: 113
  issue: 4
  year: 2020
  ident: 85_CR72
  publication-title: Int J Appl Pharm
  doi: 10.22159/ijap.2020v12i4.37307
– volume: 156
  start-page: 197
  issue: 3
  year: 1997
  ident: 85_CR13
  publication-title: J Membr Biol
  doi: 10.1007/s002329900201
– volume: 65
  start-page: 104756
  year: 2020
  ident: 85_CR80
  publication-title: Toxicol in Vitro
  doi: 10.1016/j.tiv.2019.104756
– volume: 402
  start-page: 16
  year: 2017
  ident: 85_CR74
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.05.010
– volume: 284
  start-page: 3804
  issue: 6
  year: 2009
  ident: 85_CR92
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M807191200
– volume: 1031
  start-page: 143
  issue: 2
  year: 1990
  ident: 85_CR26
  publication-title: Biochem Biophys Acta
– volume: 3
  start-page: 25
  issue: 1
  year: 2015
  ident: 85_CR18
  publication-title: J Mater Chem B
  doi: 10.1039/C4TB01401D
– volume: 15
  start-page: 1271
  issue: 1
  year: 2018
  ident: 85_CR91
  publication-title: Oncol Lett
– volume: 59
  start-page: 115
  issue: 1
  year: 2007
  ident: 85_CR19
  publication-title: Nutr Cancer
  doi: 10.1080/01635580701419030
– volume: 18
  start-page: 365
  issue: 2
  year: 2017
  ident: 85_CR45
  publication-title: Asian Pac J Cancer Prev
– volume: 50
  start-page: 573
  issue: 4
  year: 1986
  ident: 85_CR90
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(86)83497-X
– volume: 37
  start-page: 329
  issue: 1
  year: 1982
  ident: 85_CR24
  publication-title: Biophys J
  doi: 10.1016/S0006-3495(82)84681-X
– volume: 118
  start-page: 426
  issue: 2–4
  year: 1999
  ident: 85_CR47
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000024154
– volume: 2
  start-page: 66
  issue: 1
  year: 2019
  ident: 85_CR25
  publication-title: Asian J Nanosci Mater
– volume: 10
  start-page: 71
  issue: 1
  year: 2017
  ident: 85_CR57
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0442-y
– volume: 183
  start-page: 46
  year: 2012
  ident: 85_CR55
  publication-title: Adv Coll Interface Sci
  doi: 10.1016/j.cis.2012.08.002
– volume: 5
  start-page: 1332
  issue: 6
  year: 2006
  ident: 85_CR23
  publication-title: J Proteome Res
  doi: 10.1021/pr060059q
– volume: 69
  start-page: 227
  year: 2013
  ident: 85_CR1
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2013.03.011
– volume: 625
  start-page: 190
  issue: 1–3
  year: 2009
  ident: 85_CR79
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2009.08.043
– volume: 26
  start-page: 1640
  issue: 8
  year: 2015
  ident: 85_CR40
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.5b00246
– volume: 57
  start-page: 101715
  year: 2020
  ident: 85_CR3
  publication-title: J Drug Del Sci Technol
  doi: 10.1016/j.jddst.2020.101715
– volume: 151
  start-page: 325
  issue: 2
  year: 2015
  ident: 85_CR6
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-015-3406-3
– volume: 109
  start-page: 966
  issue: 6
  year: 2021
  ident: 85_CR35
  publication-title: J Biomed Mater Res A
  doi: 10.1002/jbm.a.37086
– volume: 26
  start-page: 457
  issue: 5
  year: 2009
  ident: 85_CR38
  publication-title: Clin Exp Metas
  doi: 10.1007/s10585-009-9245-z
– volume: 258
  start-page: 72
  issue: 1
  year: 2012
  ident: 85_CR44
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2011.10.009
– volume: 173
  start-page: 139
  issue: 1
  year: 1988
  ident: 85_CR12
  publication-title: Eur J Biochem
  doi: 10.1111/j.1432-1033.1988.tb13977.x
– volume: 93
  start-page: 473
  issue: 2
  year: 2013
  ident: 85_CR37
  publication-title: Surg Clin North Am
  doi: 10.1016/j.suc.2012.12.002
– volume: 1
  start-page: 208
  issue: 4
  year: 2011
  ident: 85_CR48
  publication-title: Acta Pharmaceutica Sinica B
  doi: 10.1016/j.apsb.2011.09.002
– volume: 2
  start-page: 1
  issue: 1
  year: 2017
  ident: 85_CR8
  publication-title: J Apither
  doi: 10.5455/ja.20170203075953
SSID ssj0000399909
Score 2.5317938
Snippet Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded...
BackgroundMelittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded...
Abstract Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin,...
SourceID doaj
proquest
crossref
springer
SourceType Open Website
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Anticancer properties
Apoptosis
Assaying
Biochemistry
Biocompatibility
Biomarkers
Biomedical Engineering and Bioengineering
Breast cancer
Cancer Research
Cancer therapies
Chemistry and Materials Science
Chemotherapy
Drug carriers
Encapsulation
Enzyme activity
Evaluation
Flow cytometry
Free form
Gene expression
Genes
Histopathology
Immunohistochemistry
In vivo methods and tests
Materials Science
Melittin
Mitosis
Morphology
Nano-niosome
Nanotechnology
Polydispersity
Renal and liver enzymes
Toxicity
Wound healing
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS-QwFA7iYfEiuiqOP5YcvGkwnbZp4k3dlUHQk4K3kJ8wMLYyUwX3r9_30s6MCq4Xb2mblPDeS_I98uULIUfGmVLGYWC5xW3GKDImzdCywhkkndtYVXga-eZWjO6L64fy4c1VX8gJ6-SBO8OdQmvvfcaVF6EIylhpJKyimeVeGtGJbXPF3yRTaQ6GdVclfgfKwTOhSjk_MSPF6SwDGIAHkzOWMAdT71alJN7_DnF-2CRNa8_VBlnvQSM97zq7SVZC_ZP8uOm3xbfI399hgvyKV9pE-ghlJDOzSWN88LQeN7PmMcwowFNqkYPeUoe-ntIFy_yMmpqOa_oybqcNlH338NLQpRo4_hvcMGZ9444Jsk3ur_7cXY5Yf6kCc5ALtSwIB0M8FDnn0RmwamW95NYJBVjMVyXgHYBMhfRFWbo8F97m1vMyKlNwA6bPd8hq3dRhl9DKSBcjYAhR8SJ3wShhfZSYRMGsWVYDks2Nql2vOI4XX0x0yjyk0J0jNDhCJ0doNSDHizZPnd7Gf2tfoK8WNVErO72ACNJ9BOmvImhADuae1v0AnmnUCJAKsCEfkJO595efP-_S3nd0aZ-sDTE6E23mgKy20-dwCOCntb9SnP8DsGj9PQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bSxwxFA7VQvFFtK243shD39rQzM4kk_im24oU7FMF30KusLDOlN2poL_eczKzaxUVfJtLEib5TpLvzLmEkC_WW6HSOLLSoZkxyYIpO3as8hadzl2qa4xGvvgtzy-rX1fiakiTg7Ew_9vvCyW_LwrYsTGGuGCZHjC9Rt4LWHhRmidysvqfwmGn1dmjAxPAM6mFWsbIPNvMo30op-t_xDGfmEXzbnO2RTYHmkhPely3ybvYfCQfLgZD-Cdy9yPO0KPilraJXsM1ui-zWWtDDLSZtov2Oi4oEFLq0Ou8ox7RndOVX_kxtQ2dNvRm2s1buA79zU1LH_J_Y9sw8FM2VO59Pz6Ty7OffybnbDhGgXnQfjoWpYdJHauS8-StDrJ2QXHnpQb2FWoBDAdIUqVCJYQvSxlc6QIXSduKW6tkuUPWm7aJu4TWVvmUgDXImlelj1ZLF5JCtQnWSVGPSLEcVOOHHON41MXMZF1DSdMDYQAIk4EwekS-rur87TNsvFr6FLFalcTs2PkBCI0ZJpsBiQshFBz6GquorVPQDWBKjgdlQWMbkYMl0maYsguDWQGUBjbIR-TbEv2H1y9_0t7biu-TjTHKYXaJOSDr3fxfPARi07mjLNH3ZLLtGg
  priority: 102
  providerName: Springer Nature
Title Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect
URI https://link.springer.com/article/10.1186/s12645-021-00085-9
https://www.proquest.com/docview/2543896230
https://doaj.org/article/f61ddd109d6e4e9ab8a86431b0d8a606
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgkxAviKsoG5UfeANrTpM4Ni-oKytTpU0IqNS3yLegSl0ymmwS_HrOcZxWQ2IvTuLEVpLPl8_253MIeaetzmU18Sw1uMxYiYRJPTEssxpF56YqCtyNfHEpzpfZYpWv4oRbG2WVQ5sYGmrXWJwjP8FN21JBZ80_Xf9i6DUKV1ejC42H5DABJoKuG4pVsZtj4dD7qqDyQKPwTKhcDvtmpDhpEyADuD05YYF5MHWnbwom_O_wzn-WSkMPNH9KnkTqSKc91s_IA18_J48u4uL4C_Lns9-gyuI3bSp6BecoaWabRjvvaL1u2ubKtxRIKjWoRO-oRcS3dKc1_0h1Tdc1vV132wbOXX9x29C9TXDMG8BYs5i414O8JMv52Y_ZOYuuFZiFEVHHvLBQ0X2Wcl5ZrZwojJPcWKGAkbkiB9YDxCmTLstzm6bCmdQ4nldKZ1xrKdJX5KBuav-a0EJLW1XAJETBs9R6rYRxlcShFLSdeTEiyfBTSxvtjqP7i00Zxh9SlD0QJQBRBiBKNSLvd2mue6sb9z59iljtnkSL2SGi2f4sYwUsoRQ65xIO3-ozr7SR8BnAngx3UsMobkSOB6TLWI3bcl_oRuTDgP7-9v9f6c39uR2RxxMsd0EWc0wOuu2NfwvkpjPjUIIhlPMvY3I4nS6-L-B4enb59RvEziYZhmI2DpMHEC4n07-3qPvS
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiKdYWsAHOIFV5-U4SBWitNWWdlcItVJvxq-glbZJu1mKyo_jtzHjJLsqEr31lodjJZnx-Bv7mxlC3mirM1nGniUGtxlLETGpY8NSq5F0bso8x2jk8USMTtIvp9npGvnTx8IgrbK3icFQu9riGvkWBm3LAiZr_vH8gmHVKNxd7Uto6K60gtsOKca6wI5Df_ULXLhm-2AX5P02jvf3jj-PWFdlgFlwDhbMCws679OE89LqwoncOMmNFQWAE5dnAAAAQ6TSpVlmk0Q4kxjHs7LQKddaigT6vUPWU1xAGZD1nb3J12_LVR4O838ReCaYlp6JIpN95I4UW00EcAQDpCMWsA8rrs2OoYjANeT7z2ZtmAP3H5IHHXiln1pte0TWfPWY3B132_NPyO9dP0OexxWtS3oGx0iqZrNaO-9oNa2b-sw3FGAyNciFX1CLOjenS7b7B6orOq3o5XQxr-HYtSeXNV1lJce-QR2mrHu4ZaQ8JSe38tufkUFVV_45obmWtiwBy4icp4n1uhDGlRKdObDeWT4kUf9Tle0yn2MBjpkKHpAUqhWEAkGoIAhVDMm75TPnbd6PG1vvoKyWLTFnd7hQz3-ozgQoGAfOuYjDt_rUF9pI-AzAb4Y7qcGPHJLNXtKqMySNWqn9kLzvpb-6_f9XenFzb6_JvdHx-EgdHUwON8j9GHUwkHQ2yWAx_-lfAtRamFedPlPy_baH0F-knzba
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKK1VcUHmJhQI-wAms9ebh2EgVomxXLaWrClGpN-NXqpW2SdmkReUn8qsYO86uikRvveVpxZ7x-Jv4mxmE3iijcl4mjqTabzOWbES4SjTJjPKkc10WhY9GPpqy_ZPsy2l-uob-9LEwnlbZ28RgqG1t_D_yoQ_a5gIWazosIy3ieDz5ePGT-ApSfqe1L6ehYpkFuxPSjcUgj0N3_QvcuWbnYAyyf5skk73vn_dJrDhADDgKLXHMgP67LKW0NEpYVmjLqTZMAFCxRQ5gAPBExm2W5yZNmdWptjQvhcqoUpyl0O49tFHAqg-O4Mbu3vT42_KPD4WrInBOfIp6wkTO-ygezobNCKCJD5YekYCDiLixUoaCAjdQ8D8bt2E9nGyhBxHI4k-d5j1Ea656hDaP4lb9Y_R77Oae83GN6xKfw7EnWJN5rayzuJrVTX3uGgyQGWvPi2-x8fq3wEvm-wesKjyr8NWsXdRwbLuTqxqvMpT7tkE1ZiS-3LFTnqCTOxn2p2i9qiv3DOFCcVOWgGtYQbPUOCWYtiX3jh1Y8rwYoFE_qNLELOi-GMdcBm-IM9kJQoIgZBCEFAP0bvnORZcD5Nand72slk_6_N3hQr04k9EcSJgT1toRhb66zAmlOXQDsJymlivwKQdou5e0jEalkaspMEDve-mvbv__k57f3tprtAlTSX49mB6-QPcTr4KBr7ON1tvFpXsJqKvVr6I6Y_TjrmfQX3_DOx4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Delivery+of+melittin-loaded+niosomes+for+breast+cancer+treatment%3A+an+in+vitro+and+in+vivo+evaluation+of+anti-cancer+effect&rft.jtitle=Cancer+nanotechnology&rft.au=Dabbagh+Moghaddam+Farnaz&rft.au=Akbarzadeh+Iman&rft.au=Marzbankia+Ehsan&rft.au=Farid+Mahsa&rft.date=2021-12-01&rft.pub=Springer+Nature+B.V&rft.issn=1868-6958&rft.eissn=1868-6966&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1186%2Fs12645-021-00085-9&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1868-6958&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1868-6958&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1868-6958&client=summon